In The News

Meril Life Sciences Becomes The First Indian Company To Receive European Certification For Revolutionary Stent Technology

Meril Life Sciences Becomes The First Indian Company To Receive European Certification For Revolutionary Stent Technology

Meril Life Sciences is an Indian based global medical device company that is committed to R&D, innovation in manufacturing medical technology, scientific communication and making these innovations accessible to patients. This is accomplished by our state-of-the-art production facilities, a diverse and heterogeneous R&D team and education and learning opportunities for future healthcare professionals. We believe in a culture of innovation, research and developing long-standing relationships with patients, doctors and key stakeholders.

The latest step on our journey to making healthcare accessible and improving the quality of life is our 100-micron bioresorbable vascular scaffold (BVS) becoming the first thin-strut scaffold in India to receive European Conformity (CE) mark. The MeRes100 from Meril Life Sciences, is a non-metallic mesh placed inside a narrowed artery to treat it. It has been uniquely designed to open a blocked artery, restoring blood flow and gradually dissolve over a period of 12-24 months, allowing the artery to heal and function on its own.

Receiving a European Conformity (CE) marking for the MeRes100 makes us the first company in India to achieve such a feat. This news was covered by journalist Aditya Anand from the newspaper, The Hindu. Mr. Anand visited the Meril Life Sciences headquarters in Vapi, Gujarat, to speak to the dedicated team behind MeRes100 and understand the efforts that went into creating this heart stent. Over the course of his visit, Mr. Anand met with Mr. Sanjeev Bhatt, vice-president of corporate strategy at Meril Life Sciences. To help Mr. Anand understand the innovation behind the latest MeRes technology, he explained that the role of a Drug-Eluting Stent (DES) is to provide temporary scaffolding to the blockage or lesion site in the heart and deliver a drug to facilitate better healing. What happens in most cases, is that the metallic stent remains inside the body as a permanent implant. Such a scenario can lead to an increased risk factor in the patient.

With the combined efforts of over 150 scientists, chemists, engineers and researchers Meril was able to bridge the gap between the temporary treatment of opening a heart blockage and the undesirably permanent solution of placing a metallic DES implant. The new MeRes100 bioresorbable vascular scaffold was tested in India as MeRes-1 and further studies were conducted in Brazil, Europe and Asia as MeRes-1 extend. Over a period of three years, it has been proved that the MeRes100 provides long-term safety and sustained efficacy for patients with coronary artery disease.

Dr. Praveen Chandra, chairman of interventional cardiology at Medanta Hospital, Gurgaon, who was also the co-principal investigator of the MeRes-1 study, observed that when it came to first generation bioresorbable scaffolds, the long-term results were not favorable. By contrast, the MeRes100 has reduced strut thickness, improved profile, faster degradation and a lower possibility of scaffold thrombosis. This makes the MeRes100 a giant leap forward in the field of interventional cardiology.

You can read the complete article by Mr. Aditya Anand here. All of the innovations from Meril life Sciences are born from the aim of improving the quality of human life through innovative and advanced healthcare solutions. The MeRes100 creates a minimal risk heart stent procedure with clinically proven long-term safety and efficacy. With the well-being of patients as our primary goal, Meril Life Sciences hopes to distribute and deliver path-breaking healthcare products to the entire world.